Key insights
- Alnylam presented positive clinical and real-world data for its cardiovascular treatment vutrisiran at the ACC conference. The data showed improvements in quality of life and reduced risk of mortality in ATTR-CM patients. Alnylam's strong financial health and revenue growth support continued development, potentially boosting investor confidence in the biotech sector.
CAMBRIDGE, Mass. - Alnylam Pharmaceuticals (NASDAQ:ALNY) presented clinical and real-world data from its cardiovascular portfolio at the American College of Cardiology’s Annual Scientific Session, according to a press release statement.The biotech company, valued at $42.3 billion, has achieved a "GREAT" financial health score according to InvestingPro analysis, reflecting strong operational momentum as its cardiovascular treatments advance through clinical development.
The company shared new analyses from the HELIOS-B study evaluating vutrisiran, a treatment for transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). The analyses examined health-related quality-of-life improvements, efficacy across patient subgroups, and real-world treatment adherence data.
One analysis measured quality-of-life changes using the Kansas City Cardiomyopathy Questionnaire Overall Summary Score from baseline to 30 months. Vutrisiran showed improvements in physical limitations and quality-of-life components compared to placebo. The findings were published in the European Journal of Heart Failure.
A post hoc analysis assessed patients who developed advanced disease during the study’s double-blind period. In the overall population, 8.0% of vutrisiran-treated patients developed advanced disease versus 10.7% receiving placebo. Among patients who progressed to advanced disease, vutrisiran reduced the risk of all-cause mortality and recurrent cardiovascular events by 40% in the overall population and 46% in the monotherapy population during the double-blind period.
A real-world retrospective study showed 93.8% of patients were adherent to vutrisiran treatment over a mean follow-up of 613.8 days.The positive clinical data comes as Alnylam demonstrates robust financial performance, with revenue reaching $3.71 billion in the last twelve months—representing impressive 65% year-over-year growth. The company posted diluted earnings per share of $2.33 and maintains a strong gross profit margin of 81.64%. According to InvestingPro Tips, net income is expected to grow this year, with analysts forecasting EPS of $9.65 for fiscal year 2026. Investors can access 13 additional ProTips and comprehensive financial metrics on the platform.
Alnylam also presented pooled Phase 2 safety data for zilebesiran, an investigational treatment for hypertension. The analysis covered patients with mild-to-moderate hypertension and those at high cardiovascular risk. Clinically relevant safety events including hypotension, hyperkalemia, and eGFR decline were reported as low across patient populations.
Zilebesiran is being evaluated in ZENITH, a Phase 3 cardiovascular outcomes trial initiated in September 2025. The drug is co-developed with Roche.While Alnylam’s pipeline advances, InvestingPro analysis indicates the stock is currently trading slightly above its Fair Value of $298.39. For investors seeking deeper insights, Alnylam is among the 1,400+ US equities covered by Pro Research Reports, which transform complex Wall Street data into clear, actionable intelligence through intuitive visuals and expert analysis.
In other recent news, Alnylam Pharmaceuticals has seen a series of analyst reiterations and strategic partnerships. H.C. Wainwright maintained its Buy rating with a price target of $510 following an investor webinar celebrating the first anniversary of AMVUTTRA’s approval for transthyretin amyloidosis with cardiomyopathy. Similarly, Stifel reiterated a Buy rating with a $444 price target, expressing confidence in the product’s strong launch trajectory despite potential upcoming market changes. BofA Securities also maintained a Buy rating, setting a $460 price target, while highlighting the larger-than-expected ATTR-CM market, now estimated at over 500,000 patients globally.
Morgan Stanley provided a different perspective, reiterating an Equalweight rating with a $360 price target, noting Alnylam’s strong position ahead of anticipated competition. In addition to these analyst updates, Alnylam announced partnerships with Viz.ai and the American Heart Association to enhance early detection and care coordination for ATTR-CM patients. This collaboration includes the AWARE study, which aims to integrate AI-enabled screening into clinical workflows. These developments reflect Alnylam’s ongoing efforts to strengthen its market position and improve patient outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.